Cancer immunotherapy has emerged as a powerful treatment option characterized by durable remissions and tolerable side effects.
In recent years, an unprecedented number of immune-based therapeutic modalities have been approved in the first- and second-line as well as in the adjuvant setting across a growing number of malignancies. This influx of approvals has created a need to stay current on the latest recommendations for the appropriate application of immunotherapy.
SITC Cancer Immunotherapy CONNECT is your hub to participate in live and online educational opportunities to learn more about integrating cancer immunotherapy into your practice. Download a variety of resources in the SITC Resource Library and connect with other clinicians in the Cancer Immunotherapy CONNECT Open Forum to learn more about the latest approvals, patient selection criteria, relevant biomarkers and immune-related adverse events.
Be Part of the Breakthrough at the Charles River World Congress on Animal Models in Drug Discovery & Development. Boston | September 26-27, 2017 http://breakthroughs.criver.com/index.html ...
Use of mAb-based immunotherapies has resulted in major improvements in treatment of B-cell neoplasms, but patients can relapse, succumbing to the disease. An alternative approach that destroys ...
According to the cited pharma company document within, out of Hemel Hempstead, England, May 10, 2017, Dinutuximab beta, originally developed by the Vienna-based biotech company Apeiron Biologics ...
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this ...
View More Clinician Resources
In this video, hear SITC Annual Meeting delegates explain the purpose and benefits for joining thousands of their colleagues at the Annual Meeting & Pre-Conference Programs, share how far the science of cancer immunotherapy has progressed and predict where the field is headed. Also, learn about the benefits of becoming a member of SITC.
For more than 30 years SITC (Society for Immunotherapy of Cancer) has been fighting for treatment and a cure for cancer through research and collaboration. SITC members all over the world are leading the charge against cancer. We’re traveling the globe to meet these thought leaders and demonstrate the crucial work that they’re doing to impact advances in both the science and clinical application of immunotherapy.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org